ReviewJournal of diabetes research2016
Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy.
Review in Journal of diabetes research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 158 citations in OpenAlex.
- Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with open-label extension (the EVERGREEN study).Diabetes, obesity & metabolism · 2020Trial
- Short-term renal and metabolic effects of low dose vildagliptin treatment added-on insulin therapy in non-proteinuric patients with type 2 diabetes: open-label randomized prospective study.Archives of endocrinology and metabolism · 2020Trial
- Lime powder treatment reduces urinary excretion of total protein and transferrin but increases uromodulin excretion in patients with urolithiasis.Urolithiasis · 2018Trial
- Feasibility of Integrating Urinary Proteomics and Machine Learning for Diagnosing Diabetic Nephropathy.Journal of proteome research · 2026Article
- Integrated Transcriptomic Analysis Identifies TAP1 as a Key Regulator of PANoptosis in Diabetic Kidney Disease Tubular Injury.Inflammation · 2026Article
- Splice Isoforms of the Apoptosis Gene BCL-X Have Opposing Effects in Diabetic Kidney Disease: Potential Treatment Target and Prognostic Value.Journal of diabetes research · 2026Article
- A Pilot Study of Urinary Cubilin Shedding in Type 1 Diabetes Mellitus: A Potential Biomarker to Predict Nephropathy.Journal of diabetes research · 2026Article
- Advances in the Identification of Novel Urinary Biomarkers for Diabetic Kidney Disease.Journal of diabetes research · 2026Review
- Protein-bound uremic toxin clearance as biomarker of kidney tubular function in diabetic kidney disease.Scientific reports · 2025Article
- Association between rs4673 and blood pressure response to acute saline infusion in Chinese population.Medicine · 2025Observational
- Insights into the Novel Biomarkers Expressed in Diabetic Nephropathy: Potential Clinical Applications.Current pharmaceutical design · 2025Review
- Cinnamaldehyde ameliorates obesity-induced nephropathy in C57BL/6 mice via modulation of AMPK/ACC and NF-kB pathways.Iranian journal of basic medical sciences · 2025Article
- Study on the Correlation Between Renal Blood Perfusion and Kidney Injury in Different Weekly-Aged Type 2 Diabetic Mice.Physiological research · 2024Article
- Article
- Saroglitazar suppresses KIM-1 and type IV collagen in high fat diet and low-dose streptozotocin-induced diabetic nephropathy in Wistar rats.Iranian journal of basic medical sciences · 2024Article
- The unique association between the level of plateletcrit and the prevalence of diabetic kidney disease: a cross-sectional study.Frontiers in endocrinology · 2024Article
- Urinary mitochondrial DNA may be useful in diagnosing early diabetic nephropathy.Experimental and therapeutic medicine · 2023Article
- Evaluation of urinary haptoglobin level as a biomarker of diabetic nephropathy in children with type 1 diabetes.Pediatric nephrology (Berlin, Germany) · 2023Article
- Identification of key immune-related genes and immune infiltration in diabetic nephropathy based on machine learning algorithms.IET systems biology · 2023Article
- Diagnostic efficacy of cystatin-c in association with different ACE genes predicting renal insufficiency in T2DM.Scientific reports · 2023Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) is a frequent and severe complication of diabetes mellitus (DM). Its diagnosis in incipient stages may allow prompt interventions and an improved prognosis. Towards this aim, biomarkers for detecting early DN can be used. Microalbuminuria has been proven a remarkably useful biomarker, being used for diagnosis of DN, for assessing its associated condition-mainly cardiovascular ones-and for monitoring its progression. New researches are pointing that some of these biomarkers (i.e., glomerular, tubular, inflammation markers, and biomarkers of oxidative stress) precede albuminuria in some patients. However, their usefulness is widely debated in the literature and has not yet led to the validation of a new "gold standard" biomarker for the early diagnosis of DN. Currently, microalbuminuria is an important biomarker for both glomerular and tubular injury. Other glomerular biomarkers (transferrin and ceruloplasmin) are under evaluation. Tubular biomarkers in DN seem to be of a paramount importance in the early diagnosis of DN since tubular lesions occur early. Additionally, biomarkers of inflammation, oxidative stress, podocyte biomarkers, and vascular biomarkers have been employed for assessing early DN. The purpose of this review is to provide an overview of the current biomarkers used for the diagnosis of early DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.